Syk Inhibitor

Cevidoplenib (Standard) is the analytical standard of Cevidoplenib (HY-109082). This product is intended for research and analytical applications. Cevidoplenib (SK_i-O-703) is an orally available inhibitor of spleen tyrosine K_inase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SK_i-O-592. Cevidoplenib and SK_i-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SK_i-O-592 potently inhibits multiple K_inases with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively.

Fostamatinib (disodium hexahydrate) (Standard) is the analytical standard of Fostamatinib (disodium hexahydrate). This product is intended for research and analytical applications. Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).

Asebogenin has antimalarial activity in vitro. Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps.

R406 (Standard) is the analytical standard of R406 (HY-12067). This product is intended for research and analytical applications. R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk K_inase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 reduces immune complex-mediated inflammation. R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM).

Fostamatinib Disodium (Standard) is the analytical standard of Fostamatinib Disodium. This product is intended for research and analytical applications. Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).

Cevidoplenib dimesylate (Standard) is the analytical standard of Cevidoplenib (dimesylate) (HY-109082A). This product is intended for research and analytical applications. Cevidoplenib is an orally available inhibitor of spleen tyrosine K_inase (Syk), with potential anti-inflammatory and immunomodulating activities.

Lanraplenib (Standard) is the analytical standard of Lanraplenib (HY-109091). This product is intended for research and analytical applications. Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC₅₀=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

R-348 (R-932348) choline is a potent and orally active JAK3 and Syk inhibitor. R-348 reduces IFN-γ, IL-6, and IL-10 expression. R-348 effectively diminishes acute cardiac allograft rejection.

R406 free base (Standard) is the analytical standard of R406 (free base) (HY-11108). This product is intended for research and analytical applications. R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk K_inase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation. R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM).

Mivavotinib (monohydrochloride) (Standard) is the analytical standard of Mivavotinib (monohydrochloride) (HY-100867A). This product is intended for research and analytical applications. TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).

Fostamatinib (Standard) is the analytical standard of Fostamatinib. This product is intended for research and analytical applications. Fostamatinib (R788) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM. R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM).

Syk-IN-11 (BIIB-057) is a selective Syk inhibitor with an IC₅₀ Of 13 nM. Syk-IN-11 can be used in the study of arthritis and chronic lymphocytic leukemia.